Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Long-term weight training may benefit Parkinson's disease patients

New research suggests weight training for two years significantly improves the motor symptoms of Parkinson's disease compared to other forms of exercise such as stretching and balance exercises. The clinical trial, which compared two forms of exercise for Parkinson's disease, was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

17 Feb 2012

Simple tests may help doctors determine risk of dementia, stroke in middle-aged people

Simple tests such as walking speed and hand grip strength may help doctors determine how likely it is a middle-aged person will develop dementia or stroke. That's according to new research that was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

16 Feb 2012

Alfred P. Sloan Foundation announces recipients of 2012 Sloan Research Fellowships

The Alfred P. Sloan Foundation is pleased to announce the selection of 126 outstanding U.S. and Canadian researchers as recipients of Sloan Research Fellowships for 2012. Awarded annually since 1955, the fellowships are given to early-career scientists and scholars whose achievements and potential identify them as rising stars, the next generation of scientific leaders.

16 Feb 2012

RUMC conducts early phase trial of MSDC-0160 for dementia

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.

16 Feb 2012

Disrupted sleep may raise risk of Alzheimer’s disease

According to a new study, which will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21st to April 28th, the amount of sleep people get may later affect their memory's function and the risk of Alzheimer's.

15 Feb 2012

Disrupted sleep may lead to build-up of amyloid plaques

The amount and quality of sleep you get at night may affect your memory later in life, according to research that was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

15 Feb 2012

Curcumin prolongs life and enhances activity of fruit flies with AD

Curcumin, a substance extracted from turmeric, prolongs life and enhances activity of fruit flies with a nervous disorder similar to Alzheimers. The study conducted at Link-ping University, indicates that it is the initial stages of fibril formation and fragments of the amyloid fibrils that are most toxic to neurons.

15 Feb 2012

AGS honors IU professor for outstanding achievement in geriatric care

In recognition of his significant contributions to the health care of older adults, Regenstrief Institute investigator Malaz Boustani, M.D., MPH, associate professor of medicine at the Indiana University School of Medicine, will receive the 2012 American Geriatrics Society Outstanding Scientific Achievement for Clinical Investigation Award.

15 Feb 2012

Nilvadipine phase III trial for Alzheimer's launches in Europe

A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.

14 Feb 2012

Brain tissue created from human skin cells

British scientists have successfully generated brain tissue from human skin. The team has for the first time generated a crucial type of brain cells in the laboratory by reprogramming skin cells. They say it could speed up the hunt for new treatments for conditions such as Alzheimer's disease, epilepsy and stroke.

14 Feb 2012

First Edition: February 14, 2012

Today's early morning highlights from the major news organizations include news on congressional package to payroll taxes and stop a Medicare payment cut and analysis of President Barack Obama's budget.

14 Feb 2012

Supply of childhood leukemia drug nearly exhausted

A medicine to treat children's leukemia is in such short supply that hospitals may run out within weeks; meanwhile, families of people with Alzheimer's disease are clamoring to use a skin-cancer drug after a promising study in mice.

14 Feb 2012

High calories associated with memory loss in elderly: Study

Overeating may lead to a higher risk of memory loss say researchers. A new study found that elderly who consumed more than 2,143 calories a day had more than double the risk of a type of memory loss called mild cognitive impairment (MCI) compared to those who ate fewer than 1,500 calories a day. The study appeared Sunday by the American Academy of Neurology on its website (aan.com).

13 Feb 2012

Evaluation in addition to screenings increases diagnosis rate of cognitive impairment

A new study published in the Journal of the American Geriatrics Society reveals that brief cognitive screenings combined with offering further evaluation increased new diagnoses of cognitive impairment in older veterans two to three fold.

13 Feb 2012

First Edition: February 13, 2012

Today's early morning highlights from the major news organizations preview President Barack Obama's budget, which will be released today, and examine the lingering controversy over mandates on contraceptive coverage.

13 Feb 2012

Bexarotene appears to help clear out excess plaque in Alzheimer's

"In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease," said Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), a nonprofit that identifies and funds exceptionally high-impact research worldwide through its Alzheimer's Disease Research program.

13 Feb 2012

Overeating may increase risk of MCI among the elderly

New research suggests that consuming between 2,100 and 6,000 calories per day may double the risk of memory loss, or mild cognitive impairment (MCI), among people age 70 and older. The study was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012. MCI is the stage between normal memory loss that comes with aging and early Alzheimer's disease.

13 Feb 2012

Cognitive impairment affects majority of non-demented Swedish elderly

Both subjective and objective cognitive impairment are highly common among non-demented elderly Swedes, with an overall prevalence of 39 percent and 25 percent respectively, according to a nation-wide twin-study by researchers at the Aging Research Center of Karolinska Institutet, Sweden. The study confirms higher education as a major protective factor and stresses the importance of environmental aspects over genes in mild cognitive disorders in old age.

13 Feb 2012

Deep brain stimulation helps improve memory and cognitive skills in epilepsy patients

Researchers have found that deep brain stimulation by sending in electric shocks to a part of the brain that plays a key role in memory improved people's ability to learn. This could raise hope for patients of Alzheimer’s.

12 Feb 2012

Cancer drug bexarotene effective in mouse model of Alzheimer’s

Case Western Reserve University School of Medicine neuroscientist Gary Landreth and colleagues reported Thursday that the drug - bexarotene quickly cleared away beta-amyloid plaque, believed to cause the cognitive deficits of Alzheimer's disease, from the brains of genetically engineered mice.

12 Feb 2012